Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Marc Derive et al.|The Lancet Respiratory Medicine|2023Cited by 76
Suvratoxumab Reduces Staphylococcus Aureus Pneumonia in High-Risk ICU Patients: Results of the SAATELLITE StudyBruno François, SAATELLITE Study Group, Miguel Sánchez et al.|Unknown|2019Cited by 6